NoBlood

Emergency Management of Hemorrhagic Complications in the Era of Glycoprotein IIb/IIIa Receptor Antagonists, Clopidogrel, Low Molecular Weight Heparin, and Third-generation Fibrinolytic Agents
Walter S Schroeder PharmD and Pritesh J Gandhi PharmD BCPS
19 Foster Street, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA, 01608, USA

Current Cardiology Reports 2003 5:310-317 (published 1 July 2003)

Abstract

Antithrombotic, antiplatelet, and fibrinolytic agents are the mainstay for the management of patients with acute coronary syndromes (ACS). In addition to their well-documented efficacy, these pharmacologic agents have the potential for the untoward effect of bleeding. Recent data suggest medication errors related to the dose, duration, and concomitant use of these agents contribute to increasing the risk of hemorrhage in patients treated for ACS. In the event of a major hemorrhage, clinicians should be aware of strategies used to reverse the pharmacologic effects of the offending agent. This paper critically assesses literature directed toward reversal of agents based on drug-specific pharmacodynamic and pharmacokinetic parameters.

__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email